

## **AngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System**

ALBANY, N.Y., March 14, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology/surgery, today announced it has received CE Mark certification for the Solero Microwave Tissue Ablation (MTA) System. The Solero MTA System and Accessories are indicated for the ablation of soft tissue during open, laparoscopic or percutaneous procedures. The Solero MTA System is not intended for cardiac use.

"The Solero Microwave Tissue Ablation System is a significant addition to our portfolio of oncology/surgery products and allows physicians to maximize the volume of tissue ablated in the shortest period of time," said Rick Stark, Senior Vice President and General Manager of the Oncology/Surgery division of AngioDynamics. "Solero is a single applicator system able to complete up to a 5 cm ablation in 6 minutes at maximum power."

The Solero MTA System features the Solero Microwave (MW) Generator and the specially designed Solero MW Applicators. The solid state Solero MW Generator with a 2.45 GHz operating frequency can power up to 140 W for optimized power delivery and fast ablations. The Solero MW Applicator's optimized ceramic tip diffuses MW energy nearly spherically, and its patented cooling channel with thermocouple provides real-time monitoring to help protect non-targeted tissue ablation. In addition, the Solero MTA System offers physicians scalability with a single applicator designed for multiple, predictable ablation volumes by varying time and wattage.

### **About AngioDynamics**

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. More information is available at [www.AngioDynamics.com](http://www.AngioDynamics.com).

### **Trademarks**

AngioDynamics, the AngioDynamics logo, Solero, and the Solero logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

### **Safe Harbor**

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015 and its quarterly report on Form 10-Q for the fiscal period ended August 31, 2015 and November 30, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics Inc.

Caitlin Stefanik

(518) 795-1418

[cstefanik@angiodynamics.com](mailto:cstefanik@angiodynamics.com)

Investor Relations Contacts:

FTI Consulting

Jim Polson

(312) 553-6730

[Jim.Polson@fticonsulting.com](mailto:Jim.Polson@fticonsulting.com),

Kotaro Yoshida

(212) 850-5690

[Kotaro.Yoshida@fticonsulting.com](mailto:Kotaro.Yoshida@fticonsulting.com)

Media Contact:

FTI Consulting

Kimberly Ha

(212) 850-5612

[kimberly.ha@fticonsulting.com](mailto:kimberly.ha@fticonsulting.com)

 Primary Logo

Source: AngioDynamics

News Provided by Acquire Media